



# First Quarter 2021 Results Call

## Corporate Update & Financial Results

May 6, 2021



# Forward-Looking Statements

BioCryst's presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results or performances expressed or implied in this presentation. You should not place undue reliance on the forward-looking statements. For additional information, including important risk factors, please refer to BioCryst's documents filed with the SEC and located at <https://ir.biocryst.com/financial-information/sec-filings>.

# Agenda

- ◆ Corporate Update:

Jon Stonehouse – President and Chief Executive Officer

- ◆ Global ORLADEYO™ (berotralstat) Launches:

Charlie Gayer – Chief Commercial Officer

Megan Sniecinski – Chief Business Officer

- ◆ BCX9930 Update

Dr. Bill Sheridan – Chief Medical Officer

- ◆ Financial Update

Anthony Doyle – Chief Financial Officer

- ◆ Summary and Q&A

# Significant Milestones in 2021

## Q1 2021

- ✓ **Approval** decision on ORLADEYO in Japan (January 2021)
- ✓ **Data** from completed BCX9930 dose ranging study in PNH (R&D Day: March 22)

## Q2 2021

- ✓ **Approval** decision on ORLADEYO in EU
- ✓ **Revenues** reported from Q1/first full quarter of ORLADEYO sales in US
- ✓ **Launch** of ORLADEYO in Japan
- Launch** of ORLADEYO in Germany

## Q3 2021

BCX9930 Advanced Development Trials

BCX9250 Next Steps

ORLADEYO REVENUES

# Cash position (in millions)



Cash, cash equivalents, restricted cash & investments at December 31, 2020	\$303
Cash, cash equivalents, restricted cash & investments at March 31, 2021	\$244
Senior credit facility <sup>A</sup>	\$125

A – From Athyrium Capital Management, \$125M interest-only for 5-year term

In the launch period for ORLADEYO, the company is not providing specific revenue or operating expense guidance. Based on our expectations for revenue, operating expenses, and our option to access an additional \$75 million from our existing credit facility, we believe our current cash runway takes us into 2023.

# First Quarter 2021 Results Call

## Corporate Update & Financial Results

May 6, 2021

